Clinical Trial Update: A Study of Obinutuzumab in Combination With Chemotherapy in Participants With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma [Phase 1]

View source ↗

Summary

A completed Phase 1 study evaluating obinutuzumab in combination with chemotherapy in patients with CD20+ follicular non-Hodgkin lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Non-hodgkin Lymphoma

Drugs mentioned

• Gazyva (obinutuzumab) (obinutuzumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Non-Hodgkin's Lymphoma | Phase 1 | Status: COMPLETED